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Abstract 
Objective. To quantify cells expressing mesenchymal stem cell (MSC) markers in synovial mem- branes from human 
osteoarthritic (OA) and healthy joints. 
Methods. Synovial membranes from OA and healthy joints were digested with collagenase and the isolated cells were 
cultured. Synovial membrane-derived cells were phenotypically characterized for differentiation experiments using 
flow cytometry to detect the expression of mesenchymal markers (CD29, CD44, CD73, CD90, CD105, CD117, 
CD166, and STRO-1) and hematopoietic markers (CD34 and CD45). Chondrogenesis was assessed by staining for 
proteoglycans and collagen type II, adipogenesis  by  using  a  stain  for  lipids,  and  osteogenesis  by  detecting  
calcium  deposits. Coexpression of CD44, CD73, CD90, and CD105 was determined using immunofluorescence.  
Results. Cells expressing MSC markers were diffusely distributed in OA synovial membranes; in healthy synovial 
membrane these cells were localized in the subintimal zone. More numerous MSC markers in OA synovial 
membranes were observed in cells also expressing the CD90 antigen. FACS analysis showed that more than 90% of 
OA synovial membrane-derived cells were positive for CD44, CD73, and CD90, and negative for CD34 and CD45. 
OA synovial membrane-derived cells were also positive for CD29 (85.23%), CD117 (72.35%), CD105 (45.5%), and 
STRO-1 (49.46%). Micropellet analyses showed that the culture of cells with transforming growth factor-ß3 
stimulated proteoglycan and collagen type II synthesis. 
Conclusion. Synovial membranes from patients with OA contain more cells positive for CD44, CD90, and CD105 
antigens than those from joints with undamaged cartilage. 
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The pathogenesis of osteoarthritis (OA) is characterized by the progressive destruction of articular 
cartilage. The capacity of articular cartilage for repair is limited, and the spontaneous repair that does 
occur is produced by the synthesis of a fibrocartilage1. Mesenchymal stem cells (MSC) have been 
identified in human articular cartilage from patients with OA. These progenitor cells have been implicated 
in the process of cartilage repair; however, their role in the pathogenesis of OA is incompletely 
understood2,3. 
MSC are multipotent cells having the capacity to differentiate into various cell lineages, some of 
which generate bone, cartilage, and adipose tissue4. Bone marrow MSC are characterized by the presence 
of surface markers (e.g., CD44, CD54, CD71, CD90, CD166) or their absence (e.g., CD14, CD34, CD45 
MSC)5. However, MSC show phenotypic and functional differences depending upon their tissue of origin. 
For example, MSC from bone marrow and synovial membrane have been differentiated by their gene 
expression profiles6. 
Osteoarthritic synovial membranes may be normal in appearance, showing no intimal hyperplasia or 
cellular infiltrate, or fibrotic, with increased vasculature and incorporation of fragments of cartilage and 
bone from the joint surface. Cells expressing MSC markers have been found in the intimal lining and 
subintimal layers of synovial tissue, scattered in areas with small blood vessels and lymphoid 
aggregates7,8. Data from comparative studies of MSC derived from various mesenchymal tissues suggest 
that the MSC from synovial membranes have superior capacity for chondrogenesis9,10. 
MSC from joint effusions and bone marrow aspirates show similar phenotypes and have a comparable 
capacity to form colony-forming units, or fibroblasts11,12,13,14. MSC in synovial fluid were more 
numerous in patients with OA than in healthy individuals15; however, detailed quantification studies of 
cells expressing MSC markers in synovial mem- branes have not been performed. 
When cartilage is damaged, repair mechanisms are initi- ated. Frequently a lesion of cartilage is 
covered by a fibrous tissue-like membrane with few layers of cells. This tissue could be produced to 
repair a cartilage lesion but it is not biomechanically competent, and in the end a cartilage degradation 
process may happen. We have called this “spon- taneous repair tissue,” where spontaneous repair may be 
assumed to occur. There are no studies that have focused on the quantification and distribution of the MSC 
markers from this tissue. 
The aims of our study were to identify cells with chon- drogenic capacity in the synovial membranes of 
patients with OA; to analyze quantitative differences in the number of syn- ovial membrane cells expressing 
the MSC markers CD44, CD73, CD90, and CD105, from healthy and OA human joints; and to determine 
if cells expressing these MSC mark- ers are present in spontaneous cartilage repair. In patients with OA we 
found twice as many cells expressing the MSC markers as in normal synovia. In addition, cells positive 
for CD44 and CD90 antigens were found in tissue undergoing “spontaneous repair,” whereas CD105 
antigen was not expressed by cells located in “spontaneous repair” tissue. 
MATERIALS AND METHODS 
Harvest of synovial and spontaneous repair tissues. Immediately after hip joint surgery for prosthetic 
replacement, synovial samples were obtained aseptically from 20 patients with OA (mean age 65 yrs, 
range 50–70 yrs). Synovia from normal joints was obtained from 6 organ donors with histo- logical 
normal tissue (mean age 47 yrs, range 35–55 yrs). For histological analysis hematoxylin-eosin staining 
was performed on each sample to determine whether it was normal. Synovial membranes were placed in 
ster- ile Eagle’s minimum essential medium (EMEM; Cambrex, Walkersville, MD, USA) supplemented 
with 10,000 IU/ml penicillin and 10,000 µg/ml streptomycin for transport to the laboratory. Synovial 
membrane samples from each patient were also immersed in isopentane/liquid N2 and held at –80°C until 
processed for immunostaining. 
Spontaneous repair tissue from articular cartilage was obtained from human femoral heads, from the 
fibrous areas of OA cartilage. Samples were frozen in mounting medium for further immunohistochemical 
analysis. 
This study was approved by the local ethics committee; informed con- sent was obtained from each 
patient. 
 
Immunofluorescence of synovial membranes and cartilage. Frozen sections 4 µm thick were placed on 
Superfrost Plus slides (Menzel-Glaser, Braunschweig, Germany) and fixed in acetone at 4°C for 10 min. 
Monoclonal antibodies were used for immunofluorescence detection of CD44, CD73, CD90, and CD105 
(Table 1 lists antibodies and their clones and sources). 
For CD44/CD90 and CD44/CD73 double-immunofluorescence assessment, sections were first 
exposed to mouse anti-human CD44 antibody (1:100). After incubation with rabbit anti-mouse 
immunoglobulins-FITC (1:10), the sections were exposed to mouse anti-human CD90 antibody (1:400) 
or mouse anti-human CD73-RPE antibody (1:1000). The CD44/CD90 immunofluorescence samples 
were then incubated with goat anti-mouse immunoglobulins-RPE (1:20). Immunofluorescence was green 
for CD44 and CD90 and red for CD44 and CD73. 
For CD44/CD105 or CD90/CD105 or CD73/CD105 double-immuno- fluorescence, the sections were 
first exposed to monoclonal anti-human CD105-FITC antibody (1:10). After incubation with mouse anti-
human CD44 antibody (1:100) or mouse anti-human CD90 antibody (1:400) or mouse anti-human CD73-
RPE antibody (1:1000), the CD44/CD105 and CD90/CD105 sections were incubated with goat anti-
mouse immunoglobulins-RPE (1:20). CD105 immunofluorescence was green, while CD44 or CD90 or 
CD73 immunofluorescence was red. 
To determine CD73/CD90 double-immunofluorescence, the sections were exposed to monoclonal 
mouse anti-human CD90 antibody (1:400). After incubation with rabbit anti-mouse immunoglobulins-
FITC (1:10), sections were exposed to mouse anti-human CD73-RPE antibody (1:1000). 
All incubations were accomplished within 30 min at room temperature in darkness. Between each 
incubation sections were washed in phosphate buffered saline. Negative-staining controls were obtained 
by omitting the primary antibody and incubating with the secondary antibodies conjugated with FITC or 
RPE. Nuclei were counterstained with DAPI (4’,6-diamidi- no-2-phenylindole) at 100 ng/ml for 20 min. 
The sections were mounted in glycergel (Dako, Carpinteria, CA, USA). 
Immunoperoxidase staining of paraffin-embedded tissue sections. Synovial membranes and micropellets 
were fixed in 4% paraformaldehyde and embedded in paraffin. Sections 4 µm thick were placed on 
Superfrost Plus slides and incubated with an anti-CD90 antigen monoclonal antibody (Table 1). The 
peroxidase/DAB ChemMateTM Dako EnVisionTM detection kit was employed to detect the antigen-
antibody reaction. Negative-staining controls were created by omission of the primary or secondary 
antibodies. 
Table 1. Antibodies used in this study. 
Specificity Clone Antigen Retrieval Source 
    
Flow cytometry    
RPE-CD29 MAR4  BD Pharmingen 
RPE-CD34 581  BD Pharmingen 
FITC-CD44 IM7  BD Pharmingen 
FITC-CD45 HI30  BD Pharmingen 
PE-CD73 AD2  BD Pharmingen 
PE-Cy5-CD90 5E10  BD Pharmingen 
FITC-CD105 8E11  Chemicon 
APC-CD117 YB5.B8  BD Pharmingen 
RPE-CD166 3A6  BD Pharmingen 
STRO-1 NS1-Ag4-1  Developmental Studies 
   Hybridoma Bank 
Immunohistochemistry    
Collagen type I  COL-1 Hyaluronidase Abcam 
Collagen type II  COL-2 Hyaluronidase Abcam 
Chondroitin 4 sulfate  2B6 Chondroitinase ICN Biomedicals, Inc. 
Integrin subunit ß1 4B7R  Abcam 
Keratan sulfate  5D4 Chondroitinase Seikagaku America 
CD90  5E10  BD Pharmingen 
Immunofluorescence    
Mouse anti-human CD44 HCAM DF1485  Santa Cruz Biotechnology 
Mouse anti-human CD90 (Thy-1)   BD Pharmingen 
Mouse anti-human CD105-FITC MCA1557F  Serotec 
Rabbit anti-mouse immunoglobulin-FITC   Dako 
Goat anti-mouse immunoglobulin-RPE   Dako 
    
 
RPE: R-phycoerythrin; FITC: fluorescein; PE: phycoerythrin; APC: allophycocyanin; HCAM: homing cell adhesion molecule 
 
Morphometric analysis. For each sample, 5 consecutive sections were analyzed using an Olympus BX61 
microscope connected to an Olympus DP70 digital camera. Images were acquired from 4 fields for each 
section. Cells with DAPI nuclear staining and cells with single CD44, CD73, CD90, or CD105 or double 
CD44/CD73, CD44/CD90, CD44/105, CD73/CD90, CD73/CD105, or CD90/105 immunostaining were 
independently quantified. At least 2 × 103 cells were counted for each staining experiment and 
percentages of stained cells were calculated. 
The results represent comparisons of 2 antigen pairs. In each sample, the percentage of cells positive for 
a marker was calculated by dividing the number of cells expressing the marker by the number of cells 
stained with DAPI. The percentage of cells expressing 2 markers simultaneously was calculated by dividing 
the number of cells double-positive for the 2 markers by the number of cells stained with DAPI. The 
percentage of the isolated expression of each antigen was calculated by subtracting the percentage of cells 
positive for this marker from the percentage of cells expressing both markers simultaneously. The total 
percentage of positive cells was calculated as the sum of the percentages of the isolated expression of each 
antigen and its coexpression. The results are expressed as mean ± standard deviation. 
 
Cell culture. Synovial membranes were dissected from associated tissues under sterile conditions, 
digested with 0.2% solution of collagenase type I (Gibco BRL, Life Technologies, Barcelona, Spain) in 
EMEM for 2 h at 37°C, centrifuged, and filtered through a 40-µm filter. Synovial membrane- derived 
cells (10,000 cells/cm2) were cultured in high-glucose Dulbecco’s modified Eagle’s medium (DMEM; 
Cambrex) supplemented with 20% fetal bovine serum (FBS) and 10,000 IU/ml penicillin and 10,000 
µg/ml streptomycin (both from Gibco BRL) in a humidified 5% CO2 atmosphere at 37°C. The culture 
medium was replaced twice weekly. 
When the synovial membrane-derived cells became confluent, they were released using trypsin-
EDTA (Sigma-Aldrich, St. Louis, MO, USA). To reduce contamination by fibroblasts, the resultant cell 
suspension was subjected to a preplating technique16. The basis for this technique is that synoviocytes 
require more time to attach to the culture dish than fibro- blasts. Therefore, cells that had not adhered 
within 20 min were resuspended in fresh medium and reseeded. All experiments were performed with 
cells from the second passage. 
 
Cell characterization by flow cytometry. Synovial membrane-derived cells were harvested, centrifuged, 
washed, and counted prior to flow cytometry. Cell phenotype characterization was achieved using the 
formaldehydesaponin method. The 10 antibodies listed in Table 1 were used for these experiments. 
Optimal amounts of mouse anti-human monoclonal antibodies were determined and added to each tube 
for 1 h at 4°C. A control tube for each of the chromogens received equivalent amounts of isotype 
standards. Goat anti-mouse IgG FITC-conjugate (Southern Biotechnology, Birmingham, AL, USA) was 
used as a secondary antibody when necessary. A minimum of 10,000 cell-events per assay were 
analyzed on a FACsCalibur flow cytometer (Becton Dickinson, Madrid, Spain). Statistics were calculated 
by Mann-Whitney U test. Results are expressed as percent- age positive (mean ± SD). Statistical 
significance is accepted at p < 0.05. 
 
Differentiation studies. 1. Chondrogenesis. We used a modification of the micropellet assay of Johnstone, 
et al17. Briefly, synovial membrane-derived cells from the second passage were counted and tested for 
viability using the Trypan blue dye exclusion assay. To obtain micromass cultures, 2.5 × 105 synovial 
membrane-derived cells were pelleted at 200 g for 5 min. The pelleted micromass was then cultured 3 
weeks in chondrogenic differentiation medium supplemented with recombinant human transforming 
growth factor-ß3 (rHuTGF-ß3) at 33 ng/ml (Prospecany Technogene Ltd., Rehovot, Israel). The medium 
was changed every 3 or 4 days. Molecules characteristic of hyaline cartilage, such as proteoglycans and 
collagen type II, were detected by Alcian blue staining for proteoglycans or by immuno-histochemical 
techniques. 
 
2. Adipogenesis. Synovial membrane-derived cells were seeded (2 × 105 cells/8.6 cm2) and cultured in a 
one-well chamber slide in growth medium (DMEM supplemented with 20% FBS) until confluent. 
Adipogenesis was induced by culturing for 3 weeks using adipogenic differentiation medium (Cambrex). 
After fixation in 4% paraformaldehyde, the presence of adipocytes in the cultures was determined using 
oil red O stain to visualize cytoplasmic lipid droplets. 
 
3. Osteogenesis. Synovial membrane-derived cells were seeded (5 × 104 cells/8.6 cm2) in growth 
medium in a one-well chamber slide and allowed to adhere for 24 h. Osteogenesis was induced by 
culturing for 3 weeks using osteogenic differentiation medium (Cambrex). After fixation in 4% 
paraformaldehyde, the presence of calcium deposits was assessed using alizarin red stain according to the 
standard protocol. 
 
Statistical analysis. All statistical analyses were performed using SPSS 16.0 software for Windows; p 
values < 0.05 were considered statistically significant. 
RESULTS 
Distribution and quantification of cells expressing MSC markers in synovial membranes. In this study, 
healthy and OA synovial membrane samples were analyzed for CD44, CD73, CD90, and CD105 antigens 
using double-immunofluorescence on frozen tissue and 2 antigens were analyzed simultaneously. 
The location of the CD44, CD90, and CD105 antigens in healthy and OA synovial membranes 
differed markedly (Figures 1 and 2). In healthy specimens, cells expressing these markers were located in 
the intimal lining. In OA specimens the distribution of these antigens was more diffuse and they were 
located deeper than the subintimal layer in normal synovium, around veins in the perivascular matrix. 
 
 
 
Figure 1. Cells expressing CD44, CD90, and CD105 
antigens in synovial membranes shown by 
immunofluorescence. A, B: H&E staining of healthy (A) 
and osteoarthritic (B) synovial membranes. C-H: 
Monoclonal antibodies against CD44, CD90, and CD105 
antigens were used to analyze simultaneous expression 
of 2 antigens in healthy and OA synovial membranes. 
Immunofluorescence detection of each antigen was 
achieved using frozen sections of synovial membranes. 
CD44 (green) and CD90 (red) double-immuno- 
fluorescence of healthy (C) and OA (D) synovial 
membranes; CD44 (red) and CD105 (green) double-
immunofluorescence of healthy (E) and OA (F) 
synovial membranes; CD90 (red) and CD105 (green) 
double-immunofluorescence of healthy (G) and OA (H) 
synovial membranes. Bars A and B = ~100 µm; bars C-
H = ~50 µm. 
 
 
 
Figure 2. Cells coexpressing CD44/CD73, CD73/CD90, 
and CD73/CD105 antigens in synovial membranes shown 
by immunofluorescence. A, B: H&E staining of healthy (A) 
and osteoarthritic (B) synovial membranes. C-H: 
Monoclonal antibodies against CD44, CD73, CD90, and 
CD105 antigens were used to analyze simultaneous 
expression of CD44/CD73, CD73/CD90, and 
CD73/CD105 antigens in healthy and OA synovial 
membranes. Immunofluorescence detection of each antigen 
was achieved using frozen sections of synovial membranes. 
CD44 (green) and CD73 (red) double-immunofluores- 
cence of healthy (C) and OA (D) synovial membranes; 
CD73 (red) and CD105 (green) double-
immunofluorescence of healthy (E) and OA (F) synovial 
membranes; CD90 (red) and CD105 (green) double-
immunofluorescence of healthy (G) and OA (H) syn- ovial 
membranes. Bars A and B = ~100 µm; bars C-H = ~50 
µm. 
 
Quantification studies of healthy and OA synovial mem- branes showed that they expressed the 
antigens CD44, CD73, CD90, and CD105 differently (Figure 3A). In healthy synovial membranes only a 
small percentage of cells stained positively for the MSC markers CD44, CD90, and CD105 (CD44: 1.2% 
± 0.6%; CD90: 2.1% ± 1.8%; and CD105: 1.4% ± 0.6%). In OA synovial membranes, these 
percentages were increased (CD44: 3.0% ± 1.7%; CD90: 7.7% ± 4.0%; and CD105: 2.3% ± 1.2%). 
The expressions of CD44 and CD90 were both significantly (p < 0.05) higher in OA than in healthy 
synovial membranes. Conversely, a high percentage of cells expressed the CD73 antigen in healthy 
synovial membrane (8.5% ± 3.2%), whereas this expression was reduced substantially in OA synovial 
mem- brane (1.8% ± 1.8%). 
  
 
 
 
Figure 3. A. Expression of CD44, CD73, CD90, and CD105 antigen in 
synovial membranes. Graph represents the quantitative analysis of cells 
showing expression for each marker in healthy and OA synovial membranes. 
Results are expressed as mean ± SD. *p < 0.05. B. Coexpression of 2 antigens 
in synovial membranes. Graph represents simultaneous expression of 2 
antigens (CD44/CD90, CD44/CD105, CD90/CD105, CD44/CD73, 
CD90/CD73, and CD105/CD73) in healthy and OA synovial membranes. 
Results are mean ± SD. *p < 0.05 
Analysis of the simultaneous expression of 2 antigens also showed a higher level in OA than in 
healthy synovial membranes when the analyzed antigens were CD44, CD90, and CD105 (Figure 3B). 
Coexpression of CD44 and CD90 antigens in healthy synovial membranes was observed in 0.4% ± 
0.3% of the cells, while in OA synovia 1.6% ± 0.6% of the cells stained for both antigens. Notably, 
coexpression of CD44 and CD105 antigens in healthy and OA synovial membrane (1.3% ± 0.4% vs 
2.7% ± 0.4%, respectively) was found to be higher than the coexpression of CD44 with CD90 and CD90 
with CD105. Coexpression of CD90 and CD105 antigens in healthy synovial membranes occurred in 
0.5% ± 0.5% of the cells, while 1.9% ± 1.5% of the cells in OA synovia stained simultaneously for 
these antigens. In both healthy and OA synovial membrane there were low percentages of 
coexpression of CD73 antigen with antigens CD44, CD90, and CD105. However, this coexpression was 
always slightly higher in normal synovium than in OA synovium (CD44/CD73: 0.5% ± 0.5% vs 0.2% ± 
0.1%; CD73/CD90: 0.3% ± 0.2% vs 0.0% ± 0.0%; and CD73/CD105: 0.5% ± 0.2% vs 0.3% ± 0.2%). 
The association of expression of CD44, CD73, CD90, and CD105 antigens showed differences 
between these markers and between healthy and OA synovial membranes. Only 13.4% ± 12.5% and 
1.9% ± 1.5% of CD44-positive cells were also positive for antigen CD73 in healthy and OA synovium, 
respectively. The level of coexpression of the CD44 antigen with the CD90 antigen (Figure 4A) was mod- 
erate in healthy synovial membranes, where 44.0% ± 37.6% of CD44-positive cells were also positive for 
the CD90 anti- gen, while this level doubled in OA synovia (84.2% ± 11.6% of CD44-positive cells were 
positive for CD90 antigen). In contrast, the expression of CD44 antigen showed a high level of 
association with the expression of the CD105 anti- gen in both healthy and OA synovial membranes 
(Figure 4A). Roughly 72.1% ± 12.3% of the CD44-positive cells in healthy samples and 67.2% ± 6.5% 
in OA synovial membranes were also positive for the CD105 antigen.  
 
 
 
Figure 4. Association of the expression of CD44, CD73, CD90, and CD105 
antigens in synovial membranes. Each column represents the percentage of 
positive cells for one antigen that are also positive for another antigen (black 
area in each graph) in healthy and OA synovial membranes. A. Percentage of 
CD44-positive cells expressing CD73 or CD90 or CD105. B. Percentage of 
CD90-positive cells expressing CD44 or CD73 or CD105. C. Percentage of 
CD105-positive cells expressing CD44 or CD73 or CD90. D. Percentage of 
CD73-positive cells expressing CD44 or CD90 or CD105. 
The expression of the CD90 antigen had a low level of association with the expression of CD44 or 
CD73 or CD105 in both healthy and OA synovial membranes (Figure 4B). Nearly 25% of CD90-
positive cells were also positive for the CD44 antigen or the CD105 antigen in both healthy and OA 
synovial membranes, whereas only 4.8% ± 4.7% of CD90-positive cells were positive for the CD73 
antigen in healthy synovium (coexpression of the CD90 and CD73 antigens was not observed in OA 
synovium). 
The expression of the CD105 antigen showed a high level of association with the expression of 
CD44 in both healthy and OA synovial membranes (Figure 4C); in healthy samples 87.1% ± 8.8% and in 
OA synovia 89.9% ± 8.4% of CD105-positive cells were also positive for the CD44 anti- gen. On the 
other hand, expression of the CD105 antigen was more closely associated with the expression of CD90 in 
OA than in healthy synovial membranes (Figure 4C); 33.2% ± 19.8% of the CD105-positive cells in 
healthy synovia were also positive for the CD90 antigen, while in OA synovia 68.1% ± 23.9% of 
CD105-positive cells were also positive for CD90. Expression of the CD105 antigen showed a low level 
of association with expression of the CD73 anti- gen (9.9% ± 7.5% in healthy samples and 10.2% ± 7.9% 
in OA synovial membrane). 
Expression of the CD73 antigen showed in general a low level of association with the expression of 
CD44, CD90, and CD105 (Figure 4D) in both healthy and OA synovium (with CD40: 7.7% ± 7.6% vs 
42.0% ± 27.0%; with CD90: 4.9% ± 3.6% vs 0.0% ± 0.0%; with CD105: 4.4% ± 3.6% vs 12.8% ± 
12.8%). Only a moderate association was observed with the expression of the CD44 antigen in OA 
synovium, where only 0.2% ± 0.1% of the cells coexpressed CD44/CD73 antigens. 
In summary, synovial membranes from OA patients contain higher percentages of cells positive for 
CD44, CD90, and CD105 antigens than those from joints without cartilage damage. This increased 
expression in OA synovial mem- branes was observed in greater measure to the CD90 anti- gen. 
Conversely, the percentage of cells expressing the CD73 antigen was higher in healthy synovial 
membrane than in OA synovial membrane. However, only CD44 and CD105 antigens showed high 
levels of coexpression. 
Cell-surface marker phenotype. FACS analysis demonstrated that cells derived from OA synovia 
show a cell-surface receptor pattern similar to that reported for bone marrow MSC (Figure 5). OA 
synovial membrane-derived cells were negative for CD34 and CD45 antigens. Nearly 95% of OA 
synovial membrane cells were positive for CD44, CD73, and CD90; and 45% of these cells stained for 
CD105 anti- gen. Cells isolated from OA synovia were also positive for CD29 (85.2% ± 10.5%), CD117 
(72.35% ± 15.17%), STRO-1 (49.46% ± 25.58%), CD105 (45.5% ± 8.29%), and CD166 (32.29% ± 
16.69%) (Table 2). 
 
 
 
Figure 5. Phenotype of cells isolated from synovial membranes of patients 
with OA. Antibodies listed in Table 1 were used for this procedure. Figure 
shows representative histograms of multipotential mesenchymal stem cells 
obtained from FACS analysis. Black line signifies the specific antibody; grey 
line represents the isotype control. 
Table 2. Percentage of phenotype-positive synovial membrane cells at the 
second passage (n = 20). Data are shown as mean ± SD. 
CD  Specificity Percentage of Positive Cells 
   
CD29  Alpha-1 integrin 85.2 ± 10.5 
CD44  H-CAM 99.1 ± 1.4 
CD73  Ecto-5-nucleotidase 95.1 ± 23.7 
CD90  Thy-1 98.2 ± 14.6 
CD105  SH-2, Engoglin 45.5 ± 8.3 
CD117  c-Kit, SCFR 72.3 ± 15.2 
CD166  ALCAM 32.3 ± 16.7 
STRO-1  Stromal antigen 1 49.5 ± 25.6 
   
 
  
Multilineage differentiation potential of synovial membrane-derived cells. To determine whether the 
cells from OA synovial membranes were multipotential, we cultured the cells in chondrogenic, 
adipogenic, or osteogenic differentiation media using established protocols9. 
Chondrogenesis was observed in all cell preparations analyzed (Figure 6A, 6B). Micromass cultures 
were tested for the presence of markers characteristic of hyaline cartilage using Alcian blue staining for 
proteoglycans and immunodetection of collagen type II.  Proteoglycans and collagen type II were 
located throughout the newly formed matrix, with the highest staining intensity in the core of the 
micropellets. 
 
 
 
Figure 6. Chondrogenic, adipogenic, and osteogenic capacities of synovial 
membrane cells from patients with OA. Chondrogenesis was assessed by 
incubation of micropellet cultures in chondrogenic differentiation medium and 
TGF-ß3. The resulting micromass was stained for proteoglycans with Alcian 
blue (a). Immunodetection of collagen type II is shown (b). Presence of 
adipocytes was assessed by detection of lipid droplets by oil red O staining 
(c); presence of calcium deposits was determined by staining with alizarin red 
(d). Original magnification ×100 for all photographs 
Synovial membrane-derived cells cultured in adipogenic medium developed lipid droplets, an 
indicator of adipogenic differentiation (Figure 6C). The osteogenic potential of synovial membrane-
derived cells cultured in osteogenic media was demonstrated using alizarin red stain to show calcification 
(Figure 6D). 
Quantification of cells expressing CD44, CD90, and CD105 antigens in “spontaneous repair” tissue. 
Analysis of localized spontaneous repair tissues covering the OA-damaged cartilage showed cells that 
expressed the characteristic antigens of MSC (Figures 7A, 7B), such as CD44 (10.2% ± 1.5%) and 
CD90 (12.3% ± 2.1%). The expression of CD44 was only slightly associated with the expression of 
CD90 antigen; only 0.71% ± 0.5% of cells coexpressed both anti- gens. In spontaneous repair tissue 5.6% 
of CD44-positive cells were also positive for CD90, and 6.7% of CD90-positive cells were also positive 
for CD44 antigen. Interestingly, the CD105 antigen was not present in spontaneous repair tissue. 
  
DISCUSSION 
This study confirms for the first time that OA synovia contain more cells expressing MSC markers 
than do synovial membranes from healthy joints. In addition, we demonstrated that synovial membranes 
from patients with OA contain MSC with chondrogenic capacity and that “spontaneous repair” tissue 
from OA cartilage contains cells expressing MSC markers. 
The presence of MSC in synovial membranes was recently reported7,8. These investigators defined 
the cells as mesenchymal because of their phenotypic profile and potential for differentiation; these cells 
were also shown to have ultrastructural and morphologic features similar to B synoviocytes18. Although 
there are no specific markers to identify MSC, a number of monoclonal antibodies for phenotypically 
characterizing these tissue-derived stem cells have been developed5. The general consensus is that MSC 
should be negative for the hematopoietic markers CD34 and CD45, and positive for CD44, CD73, CD90, 
and CD1054. 
The culture conditions used to isolate MSC from the synovium are similar to those used to obtain 
fibroblastic synoviocytes and are based, in part, on the fact that synoviocytes require more time to attach 
to the culture dish than MSC. This suggests that only a subset of cells in the synovium-derived cell 
population is constituted of stem cells. Because no specific marker for MSC is presently available, MSC 
characterization is currently based on their functional properties. To improve the number of MSC isolated 
from synovial membranes, we used a preplating technique that minimizes the number of contaminating 
fibroblasts in the culture16. We used surface markers found on cells with multipotential properties to 
phenotypically characterize MSC. Our cell population was phenotypically characterized by simultaneous 
positive staining for CD44, CD73, and CD90; nearly 95% of all MSC expressed these antigens, 
which have been identified as markers for undifferentiated bone marrow MSC and synovium-derived 
adherent cells6,12,13,19. 
In addition, we demonstrated that, under appropriate conditions, synovial membrane-derived cells can 
differentiate into chondrocytes, adipocytes, or osteoblasts. These findings indicate that synovia from OA 
patients have a cell population with multilineage properties possessing phenotypic markers similar to 
those observed for bone marrow MSC. These results confirm that the synovial membrane-derived cells 
observed in our study could be legitimately designated as MSC. 
A previous quantitative study of the MSC population in OA synovia has been performed; however, 
the study employed flow cytometry and did not compare OA with normal synovia8. We carried out for 
the first time a comparative semiquantitative study of cells expressing MSC markers using OA and 
normal synovial samples. We were also able to elucidate the tissue distribution of MSC in synovial 
membranes and show that OA synovia contain a higher number of cells expressing MSC markers than 
normal synovia. 
The presence of cells expressing MSC markers in the synovial tissues of patients with OA raises the 
question whether these cells appear in the joint as a result of inflammatory processes or whether they are 
already present prior to onset of the disease. It has been suggested that mesenchymal cells are among the 
earliest cells to arrive in the prearthritic joint15. In an effort to resolve this question, we were able to 
demonstrate that the synovial tissue of healthy donors contains MSC markers before any active articular 
inflammatory process occurs. We also note that during degenerative inflammatory processes a number of 
our OA cases presented with typical features of an inflammatory condition with chronic synovitis, 
including intimal cell hyperplasia and infiltration of lymphocytes, plasma cells, and 
monocyte/macrophage cells. The inflammatory cells found in synovial membranes are derived from bone 
mar- row and transported through the vascular system and peripheral blood. MSC may also migrate to 
OA synovial mem- branes in the same way. We demonstrated that CD44/CD90 is located in the 
subintimal zone and around blood vessels in the synovium. Other investigators suggest that canals 
between the bone marrow and synovium allow migration of bone marrow MSC into the synovium of 
inflamed joints2. Because activated osteoclasts were found in close proximity to enlarged canals, the 
mechanism of formation of bone canals is at least partly osteoclast-mediated2. 
When a tissue is damaged, repair mechanisms are initiated that involve stem cells and inflammatory 
cells already in the compromised tissue or migrating to it through the vascular system. Because articular 
cartilage is avascular, it must either self-repair or rely on neighboring tissues for repair. It has been 
reported that human articular cartilage tissue has MSC that may participate in the repair of cartilage 
lesions2. A further factor in the repair process involves the synovial membrane as a potential source of 
nutrients and other factors that modulate cartilage repair
13,20
. It is possible that the MSC having 
chondrogenic potential that are present in the synovial membrane can migrate to the damaged cartilage to 
participate in the active process of cartilage regeneration and repair. In support of this possibility, MSC 
have been found in the synovial fluid of patients with OA15. We analyzed the tissue covering damaged 
cartilage in patients with OA (we have called this “spontaneous repair tissue”), where spontaneous tissue 
repair may be assumed to occur, and found cells expressing MSC markers (CD44 and CD90) that show a 
phenotype similar to MSC identified in OA synovial membranes. Although cells expressing MSC 
markers are located in spontaneous repair tissue of patients with OA, the capacity of these cells to repair 
cartilage may be limited by the cartilage degradation progress. The finding that the CD105 antigen is not 
expressed by cells located in repair tis- sue could suggest that these cells are necessary for repair 
processes to be effective in OA cartilage. 
In summary, cells with the characteristic phenotype of MSC were isolated from OA synovial 
membranes. These cells have the capacity to differentiate into chondrocytes in vitro. Synovial membranes 
from patients with OA contain more cells expressing MSC markers than do those from joints with no 
cartilage damage. Spontaneous cartilage repair tissue contains cells positive for CD44 and CD90, but the 
CD105 antigen was absent. 
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